Time filter

Source Type

Stanford, CA, United States

Clement-Duchene C.,Stanford Clinical Cancer Center | Clement-Duchene C.,University of Lorraine | Wakelee H.,Stanford Clinical Cancer Center
Journal of Thoracic Oncology | Year: 2010

Although lung cancer therapy has slowly improved with standard cytotoxic chemotherapy drugs, we have reached an efficacy plateau. The addition of targeted agents, such as those with antiangiogenesis activity, to chemotherapy can improve response and survival outcomes. The first of these agents to gain approval in lung cancer in October 2006 was the antivascular endothelial growth factor antibody, bevacizumab. Small molecule tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor also have proven activity and are under active investigation. Vascular disrupting agents target existing tumor vasculature leading to tumor necrosis, and are being studied in solid tumors, including lung cancer, both as single agents and in combination with chemotherapy. This article will review these new targeted antiangiogenic and antivascular agents with a focus on their use as lung cancer therapeutics. Copyright © 2009 by the International Association for the Study of Lung Cancer.

Discover hidden collaborations